CONNECTA Therapeutics selected for funding under the EIC Accelerator
The European Innovation Council (EIC) announced yesterday that CONNECTA Therapeutics has been selected for grant and equity funding, following the last EIC Accelerator cut-off.
CONNECTA Therapeutics is honored to be part of the 71 European companies selected among 1211 submitted proposals in the most competitive funding round so far since the launch of the Accelerator under Horizon Europe.
The EIC funding will boost CONNECTA’s neurodevelopmental clinical developments in Fragile X syndrome, a rare disease that represents a huge public health challenge.
The EIC Accelerator is a funding programme under Horizon Europe that offers support to start-ups and SMEs that:
- have a innovative, game changing product, service or business model that could create new markets or disrupt existing ones in Europe and even worldwide,
- have the ambition and commitment to scale up,
- are looking for substantial funding, but the risks involved are too high for private investors alone to invest.
More information: